ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
期權訓練營
投資學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
獎項與榮譽
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
AdvisorShares Psychedelics ETF
24.44
-0.6755
-2.69%
成交量:
4.39萬
成交額:
107.15萬
市值:
5,671.07萬
市盈率:
- -
高:
25.32
開:
25.32
低:
24.14
收:
25.12
52周最高:
27.02
52周最低:
15.63
股本:
232.00萬
流通股本:
232.00萬
量比:
1.72
換手率:
1.89%
股息:
1.70
股息率:
6.97%
淨資產收益率:
--
總資產收益率:
--
市淨率:
--
市盈率(LYR):
- -
資料載入中...
總覽
公司
新聞資訊
公告
概念
沒有相關數據
資金流向
資金流入:
資金流出:
實時
日
周
月
季度
年
新聞資訊
Compass Pathways在2026年精神病學大會上於美國啓動‘改變難治性抑鬱症的旋律’項目,深化醫療專業人士認知
美股速递
·
昨天
專家敦促美國食品藥品監督管理局(FDA)為迷幻藥物制定明確的安全和獲取標準
路透中文
·
昨天
Compass Pathways公布美國資助計劃入選者,旨在推進Comp360獲批後供應商培訓項目
美股速递
·
09/10
Compass Pathways 25毫克組在第52周實現MADRS平均降低13點,療效持續至一年
美股速递
·
09/09
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投,即時串流報價與多種工具,立即開戶享更多優惠!","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投,即時串流報價與多種工具,立即開戶享更多優惠!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/hant/stock/PSIL"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PSIL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","market":"US","secType":"STK","nameCN":"AdvisorShares Psychedelics ETF","latestPrice":24.4445,"timestamp":1789492058805,"preClose":25.12,"halted":0,"volume":43945,"delay":0,"changeRate":-0.02689092356687896,"floatShares":2319976,"shares":2319976,"eps":0,"marketStatus":"交易中","change":-0.6755,"latestTime":"09-15 13:10:29 EDT","open":25.3215,"high":25.3215,"low":24.14,"amount":1071452.9276,"amplitude":0.047034,"askPrice":24.66,"askSize":1000,"bidPrice":24.17,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789502400000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":25.12,"sharesOutstanding":1184976,"nav":24.85,"aum":57650992.8,"dividendRate":0.069672,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":25.12,"preClose":25.12,"latestTime":"19:30 EDT","volume":167,"amount":4194.275,"timestamp":1789428602004,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.717425,"impliedVol":0.4632,"impliedVolPercentile":0.8207},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","floatShares":2319976,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.717425,"shares":2319976,"dividePrice":1.7031,"high":25.3215,"amplitude":0.047034,"preClose":25.12,"low":24.14,"week52Low":15.6348,"pbRate":"--","week52High":27.0175,"institutionHeld":0,"latestPrice":24.4445,"committee":-0.818182,"eps":0,"divideRate":0.069672,"volume":43945,"delay":0,"ttmEps":0,"open":25.3215,"prevYearClose":17.17,"prevWeekClose":24.7682,"prevMonthClose":24.62,"prevQuarterClose":24.05,"fiveDayClose":24.96,"twentyDayClose":25.83,"sixtyDayClose":20.0904},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PSIL\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PSIL","amount":1.68387,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-29","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-29"},{"date":"2025-09-22","symbol":"PSIL","amount":0.02007,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-29","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-29"},{"date":"2025-06-23","symbol":"PSIL","amount":0.01191,"announcedDate":"2025-06-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"},{"date":"2025-03-21","symbol":"PSIL","amount":0.16343,"announcedDate":"2025-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-21","defaultRemindTime":1742563800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-28","payableDate":"2025-03-21","currency":"USD","dateTimestamp":1742529600000,"payDate":"2025-03-28"},{"date":"2024-12-23","symbol":"PSIL","amount":0.05477,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-30","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-30"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PSIL\",market:\"US\",,,undefined,":[{"executeDate":"2022-09-26","recordDate":"2022-09-27","paymentDate":"2022-09-30","value":0.05421,"currency":"USD"},{"executeDate":"2023-09-25","recordDate":"2023-09-26","paymentDate":"2023-09-29","value":0.00336,"currency":"USD"},{"executeDate":"2024-09-23","recordDate":"2024-09-23","paymentDate":"2024-09-30","value":0.1087,"currency":"USD"},{"executeDate":"2024-12-23","recordDate":"2024-12-23","paymentDate":"2024-12-30","value":0.05477,"currency":"USD"},{"executeDate":"2025-03-21","recordDate":"2025-03-21","paymentDate":"2025-03-28","value":0.16343,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PSIL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PSIL\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1111501056","title":"Compass Pathways在2026年精神病學大會上於美國啓動‘改變難治性抑鬱症的旋律’項目,深化醫療專業人士認知","url":"https://stock-news.laohu8.com/highlight/detail?id=1111501056","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111501056?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 18:31","pubTimestamp":1789468272,"startTime":"0","endTime":"0","summary":"在即将召开的2026年精神病学大会上,COMPASS Pathways plc正式宣布于美国市场推出全新倡议——“改变难治性抑郁症的旋律”。该项目的核心目标在于拓宽医疗保健专业人士对难治性抑郁症的理解边界,推动临床认知的迭代升级。在2026年精神病学大会这一汇聚全球精神健康领域顶尖专家的平台上,该项目无疑将占据重要位置。COMPASS Pathways此举,也标志着其在推动精神健康治疗创新道路上迈出了坚实一步,超越了药物研发本身,深入到医疗生态系统的神经中枢。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PSIL","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667962699","title":"專家敦促美國食品藥品監督管理局(FDA)為迷幻藥物制定明確的安全和獲取標準","url":"https://stock-news.laohu8.com/highlight/detail?id=2667962699","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667962699?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 06:39","pubTimestamp":1789425555,"startTime":"0","endTime":"0","summary":"此次听证会是美国总统唐纳德·特朗普政府自4月 以来,为推动合格的迷幻药物项目 进入市场所开展的、历时数月的最新举措。发言者敦促研究人员收集有关月经周期、妊娠及产后状况、围绝经期、绝经期、激素水平及合并用药的数据,并警告称汇总结果可能会掩盖疗效或不良事件方面的差异。“FDA对安全性和有效性的评估……必须始终是未来任何临床应用的基础,”美国精神病学协会表示。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nL4S4561NY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX","PSIL","BK4139","CMPS","GHRS","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100081863","title":"Compass Pathways公布美國資助計劃入選者,旨在推進Comp360獲批後供應商培訓項目","url":"https://stock-news.laohu8.com/highlight/detail?id=1100081863","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100081863?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 18:36","pubTimestamp":1789036568,"startTime":"0","endTime":"0","summary":"Compass Pathways正式揭晓了美国资助计划的获选名单。这项计划聚焦于Comp360产品在获得监管批准之后的供应商培训事宜。通过这一举措,公司希望为相关培训体系的搭建提供有力支持。入选的机构将在后续阶段发挥关键作用,协助推动培训内容的开发与实施。此次公布的名单标志着该计划进入实质性推进阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PSIL","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168737220","title":"Compass Pathways 25毫克組在第52周實現MADRS平均降低13點,療效持續至一年","url":"https://stock-news.laohu8.com/highlight/detail?id=1168737220","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168737220?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 18:36","pubTimestamp":1788950183,"startTime":"0","endTime":"0","summary":"Compass Pathways的25毫克剂量组在第52周呈现出平均13分的MADRS评分降幅,且这一改善效果能够稳定维持长达一年之久。这一结果不仅彰显了治疗方案的持续有效性,也为其在长期临床应用中提供了有力佐证。疗效的持久性无疑成为该研究中最引人瞩目的亮点之一。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","BK4139","CMPS"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":5,"pageCount":1,"totalSize":20,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/PSIL\",params:#limit:6,delay:false,,,undefined,":[]}}